NCT01660880

Completed

Validation of Receptor Occupancy Simulation

Seoul National University Hospital Source

Other study identifiers

Sponsor study identifier

C-1205-094-410

Secondary identifiers

A070001

OTHER_GRANT · The Korean Healthcare Technology R&D Project

Study Type

observational

Actual enrollment (reported)

7

Locations

1 country

Sites

1

Timeline

Study Start

December 2012

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2013

Actual (reported)

Study Completion

April 2014

Actual (reported)

Brief Summary

To estimate dopamine receptor occupancy by aripiprazole using computer simulation
To measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics
To validate the simulation result by comparing the receptor occupancy from the simulation with that from the patients

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 7 participants
Study completion date: April 2014
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
July 23, 2012
Actual (reported)
First Posted
August 9, 2012
Actual (reported)
Study Start
December 2012
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
December 2013
Actual (reported)
Study Completion
April 2014
Actual (reported)

Last Updated: April 8, 2019
Status Verified: April 2019
Last Update Submitted: April 4, 2019

Conditions

Dopamine Receptor Occupancy Medication Satisfaction Prolactin Level Schizophrenia

Outcome Measures

Primary Outcomes (1)

Dopamine receptor occupancy
Measured using 11C-raclopride positron emission tomography
72 hrs after the last administration

Secondary Outcomes (10)

Hamilton rating scale for depression
Baseline and 72 hours after the last administration
Barnes akathisia scale
Baseline and 72 hours after the last administration
Abnormal involuntary movement scale
Baseline and 72 hours after the last administration
Simpson-Angus scale
Baseline and 72 hours after the last administration
Treatment satisfaction questionnaire for medication
Baseline and 72 hours after the last administration
+5 more secondary outcomes

Study Arms (1)

aripiprazole

Patient group who is treated with aripiprazole

Eligibility Criteria

Age20 Years - 55 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Patients with schizophrenia who is in the steady sate of antipsychotic treatment

You may qualify if:

clinical diagnosis of schizophrenia

Sponsors & Collaborators

Seoul National University Hospital
Otherlead

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

Jun Soo Kwon, M.D., Ph.D.
Seoul National University Hospital
PRINCIPAL INVESTIGATOR

Enrollment

7 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

July 23, 2012

First Posted

August 9, 2012

Study Start

December 2012

Date type not reported

This date has not been verified as actual or estimated.

NCT01399450

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Phase 4Completed

NCT01860781

The Effect of Paliperidone Palmitate in Schizophrenia

Phase 4Completed

NCT01562808

Change in Brain Metabolism and Cognitive Function by Aripiprazole

Not ApplicableCompleted

NCT02884518

Predicting Antipsychotic Discontinuation in Psychosis

Not ApplicableUnknown

NCT00328367

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Phase 4Completed

NCT02451371

Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophrenia

Phase 1/2Completed

treated with aripiprazole or risperidone

no change in dose of antipsychotics for at least 6 weeks

total PANSS score should be below 80

You may not qualify if:

Other psychiatric disorders rather than schizophrenia
history of head trauma
positive in urine hCG
on antidepressant, anticholinergics or mood stabilizer

Contact the study team to confirm eligibility.

Primary Completion

December 2013

Actual (reported)

Study Completion

April 2014

Actual (reported)

Last Updated

April 8, 2019

Record last verified: 2019-04

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01660880
Data provider: ClinicalTrials.gov
Source updated: 2019-04-08
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:06 UTC

Locations

KR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (10)

Study Arms (1)

aripiprazole

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations